CareDx, Inc

NASDAQ:CDNA

Medical - Diagnostics & Research

Healthcare
$74.44 +5.07%

+$1.19 today

Market cap
$3.91B
Beta
2.48
P/E (TTM)
-154.0
EPS (TTM)
-$0.16
52W Low $10.96High $24.96

Volume 0.54M

Average 0.74M

CDNA Common Stock Repurchased

Cash spent buying back the company's own shares.

CareDx, IncNASDAQ: CDNA

Common Stock Repurchased · Q2 FY2026 · quarter ended Jun 2026

Common stock repurchased turns positive

Q2 FY2026 common stock repurchased was $0, compared with -$50M a year earlier. Trailing-twelve-month common stock repurchased was -$37.77M. Over 3 fiscal years it compounded at +415.2% a year.

Context

  • Common stock repurchased amounted to 23.1% of revenue in FY2025, up 23.0 pp from a year earlier.
  • Common stock repurchased grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly common stock repurchased holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$9.44M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
-$87.77M+16713.8% YoY
LTMJun 2026
-$37.77M-24.5% YoY
Common Stock Repurchased past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.0%——
1 year+16713.8%——
3-year CAGR+415.2%——
5-year CAGR——
10-year CAGR——

Common Stock Repurchased history

USD · from the cash flow

Latest · FY2025
(87.77M) USD
Year-over-year change
-16713.8%

Common Stock Repurchased vs competitors

How CDNA compares with its peers on the latest reported figures

  • CDNA's LTM Jun 2026 common stock repurchased of $37.77M is the 3rd largest of the 8 companies compared; the peer median is $0.
  • Its year-over-year change of -24.5% is the lowest of 3, against a peer median of +169.8%.
  • Common stock repurchased amounts to 8.2% of revenue for CDNA, versus a peer median of 0.0%.
CDNA Competitors Peer median
Common Stock Repurchased for CDNA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
QGENQiagen N.V.LTM Jun 2026$508.79M +71.0%+129.7%24.2%
FLGTFulgent Genetics, Inc.LTM Mar 2026$43.43M +268.6%-43.2%13.6%
CDNACareDx, IncLTM Jun 2026$37.77M -24.5%+415.2%8.2%
VCYTVeracyte, Inc.LTM Jun 2026$4.29M ——0.8%
NTRANatera, Inc.LTM Jun 2026$0 ——0.0%
BLLNBillionToOne, Inc.LTM Jun 2026$0 ——0.0%
WGSGeneDx Holdings Corp.LTM Jun 2026$0 ——0.0%
MYGNMyriad Genetics, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding CDNA) $0+169.8%+43.2%0.0%

Competitors are the stored peer set for CDNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(30.66M)(76.61M)(190.28M)52.55M(21.35M)
Depreciation & Amortization11.89M16.01M19.82M19.76M20.42M
Deferred Income Tax00566K(187K)17K
Stock-Based Compensation36.08M46.55M49.09M66.41M34.86M
Change in Working Capital(40.97M)(14.22M)106.03M(102.31M)3.81M
Accounts Receivables(24.42M)(6.66M)16.02M(13.74M)22.52M
Inventory(6.93M)(2.86M)54K(1.02M)(4.96M)
Accounts Payables1.79M(2.05M)2.9M(5.11M)808K
Other Working Capital(11.42M)(2.64M)87.06M(82.44M)(14.56M)
Other Non-Cash Items4.37M3.03M(3.61M)1.83M4.28M
Operating Cash Flow(19.29M)(25.24M)(18.39M)38.05M42.03M
Capital Expenditures(20.26M)(24.33M)(9.24M)(6.48M)(5.91M)
Acquisitions (Net)(15.43M)(610K)(6.68M)00
Purchases of Investments(5.5M)(315.15M)(201.17M)(160.29M)(145.93M)
Sales of Investments88.91M111.59M256.04M166.92M154.67M
Other Investing Activities001.5M(634K)0
Investing Cash Flow47.71M(228.5M)40.45M(483K)2.16M
Debt Repayment(66K)0000
Common Stock Issued188.86M0008M
Common Stock Repurchased0(642K)(27.54M)(522K)(87.77M)
Dividends Paid00000
Other Financing Activities(3.15M)(3.89M)(2.07M)(5.08M)(13.62M)
Financing Cash Flow185.64M(4.54M)(29.61M)(5.61M)(93.39M)
Effect of Forex Changes(303K)23K(112K)532K(90K)
Net Change in Cash213.76M(258.25M)(7.66M)32.49M(49.29M)
Free Cash Flow(39.55M)(49.57M)(27.63M)31.56M36.12M

CareDx, Inc

NASDAQ:CDNA

Intrinsic Alpha fair value

Locked

Current Price

$74.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.